Scientists moved a step closer toward coaxing the body into producing its own replacement blood vessels after discovering that suppressing parts of the innate immune system may raise the chances of a tissue engineered vascular graft's success. In a report appearing in the May 2015 issue of The FASEB Journal scientists showed that

A new study found that drugs used to treat multiple sclerosis have soared in price in the past two decades, in some cases more than 700 percent, even though newer drugs have come to the market - a process that normally should have stabilized or reduced the cost of at least the older medications.

The team led by Dr Sheena Cruickshank of the Faculty of Life Sciences and Professor Andy Brass from the School of Computer Science (University of Manchester) analysed 58 papers on research into inflammatory bowel disease published between 2000 and 2014. They found a wide variety in how methods were reported and that vital information about experiments were missing, meaning they couldn't be accurately reproduced in animal or human models.

Fastening protein-based medical treatments to nanoparticles isn't easy. With arduous chemistry, scientists can do it. But like a doomed marriage, the fragile binding that holds them together often separates. This problem, which has limited how doctors can use proteins to treat serious disease, may soon change.

According to the World Health Organization's 2014 World Malaria Report, there are an estimated 198 million cases of malaria worldwide with 3.3 billion people at risk for contracting the infection. Although the impact of malaria is still significant, the statistics reflect a considerable reduction in the global malaria burden.

Researchers are beginning to explore whether the genetics of patients who experience a placebo effect are different from those of patients who don't. It's well known that people can feel better if they believe they are receiving treatment, but the biological pathways involved are relatively unexplored.

An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. has developed a quick-acting vaccine that is both safe and effective with a single dose against the Ebola strain that killed thousands of people in West Africa last year.